SCHEMBL6709484

SCHEMBL6709484

CCOC(=O)/C(=C/Nc1ccc(F)c(F)c1)C(=O)c1cc(CN2CCOCC2)ccc1F

nearest known ligand 0.46

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.46
RAB9A P51151 5/20 0.45
SMN1; SMN2 Q16637 5/20 0.45
LMNA P02545 3/20 0.45
MAPT P10636 2/20 0.45
MAPK1 P28482 2/20 0.45
TSHR P16473 1/20 0.45
STAT3 P40763 1/20 0.45
NPC1 O15118 4/20 0.45
TP53 P04637 2/20 0.45
NPSR1 Q6W5P4 3/20 0.44
KDM4E B2RXH2 3/20 0.44
POLB P06746 2/20 0.44
DHODH Q02127 1/20 0.41
CACNA1B Q00975 1/20 0.41
APBA1 Q02410 1/20 0.41
SAE1 Q9UBE0 1/20 0.41
UBA2 Q9UBT2 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6709488 1.00 ALDH1A1 (0.46) ALDH1A1RAB9ASMN1; SMN2LMNAMAPT
SCHEMBL6710843 0.92 SMN1; SMN2 (0.46) RAB9ASMN1; SMN2LMNAMAPTMAPK1
SCHEMBL6709470 0.92 SMN1; SMN2 (0.46) RAB9ASMN1; SMN2LMNAMAPTMAPK1
SCHEMBL6709485 0.91 NPSR1 (0.47) ALDH1A1RAB9ASMN1; SMN2LMNAMAPT
SCHEMBL6709489 0.91 NPSR1 (0.47) ALDH1A1RAB9ASMN1; SMN2LMNAMAPT
SCHEMBL6711016 0.91 LMNA (0.48) ALDH1A1RAB9ASMN1; SMN2LMNAMAPT
SCHEMBL6711020 0.91 LMNA (0.48) ALDH1A1RAB9ASMN1; SMN2LMNAMAPT
SCHEMBL6708280 0.91 HIF1A (0.48) ALDH1A1RAB9ASMN1; SMN2LMNAMAPT
SCHEMBL6708277 0.91 HIF1A (0.48) ALDH1A1RAB9ASMN1; SMN2LMNAMAPT
SCHEMBL6709468 0.90 MAPK1 (0.43) ALDH1A1RAB9ASMN1; SMN2LMNAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040024209-A1 1-Aryl-4-oxo-1,4-dihydro-3-quinolinecarboxamides as antiviral agents SCHNUTE MARK E (US) 2004-02-05 US disclosed
US-6653307-B2 Such as N-(4-chlorobenzyl)-6-(4-morpholinylmethyl)-4-oxo-1-phenyl-1,4-dihydro-3-quinolinecarboxamide for treatment of herpes virus; viral DNA polymerase inhibitors PHARMACIA & UPJOHN COMPANY 2003-11-25 US disclosed
EP-1292575-A2 1-ARYL-4-OXO-1,4-DIHYDRO-3-QUINOLINECARBOXAMIDES AS ANTIVIRAL AGENTS PHARMACIA & UPJOHN COMPANY (US) 2003-03-19 EP disclosed
US-20020103220-A1 1-Aryl-4oxo-1,4-Dihydro-3-quinolinecarboxamides as antiviral agents PHARMACIA & UPJOHN COMPANY 2002-08-01 US disclosed
WO-2001098275-A2 1-ARYL-4-OXO-1,4-DIHYDRO-3-QUINOLINECARBOXAMIDES AS ANTIVIRAL AGENTS PHARMACIA & UPJOHN COMPANY (US) 2001-12-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040024209-A1 1-Aryl-4-oxo-1,4-dihydro-3-quinolinecarboxamides as antiviral agents ZC3HAV1, ZC3HAV1L, IRF3 ALDH1A1 668/4885RAB9A 2067/4885SMN1; SMN2 4052/4885
US-20020103220-A1 1-Aryl-4oxo-1,4-Dihydro-3-quinolinecarboxamides as antiviral agents ZC3HAV1, IRF3, ZC3HAV1L ALDH1A1 463/4885RAB9A 2302/4885SMN1; SMN2 4347/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.